Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.69 USD
Change Today +0.22 / 3.40%
Volume 274.2K
FATE On Other Exchanges
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

fate therapeutics inc (FATE) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/15 - $8.78
52 Week Low
12/12/14 - $3.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FATE THERAPEUTICS INC (FATE)

Related News

No related news articles were found.

fate therapeutics inc (FATE) Related Businessweek News

No Related Businessweek News Found

fate therapeutics inc (FATE) Details

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular therapeutics for the treatment of severe, life-threatening diseases. It has a platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. The company focuses primarily on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. The company’s lead product candidate is ProHema, an ex vivo programmed hematopoietic cellular therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies in adults; in Phase Ib clinical development for hematologic malignancies in pediatric patients; and in Phase Ib clinical development for inherited metabolic disorders in pediatric patients. It is also developing a triple modulator combination of pharmacologic modulators that programs human CD34+ cells to express high levels of PD-L1, a key immunosuppressive protein; and in vivo therapeutic potential of PD-L1 programmed CD34+ cells to selectively home to sites of, and suppress, T cell proliferation, and cytokine production. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

50 Employees
Last Reported Date: 03/12/15
Founded in 2007

fate therapeutics inc (FATE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Operating Officer and Chief Financial O...
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2014.

fate therapeutics inc (FATE) Key Developments

Fate Therapeutics, Inc. Signs Research Agreement with Boston Children's Hospital

Fate Therapeutics, Inc. has signed a two-year sponsored research agreement with Boston Children's Hospital to develop an adoptive immunoregulatory cell therapy to treat autoimmune diseases. The collaboration seeks to assess the potential of Fate's PD-L1 programmed CD34+ cellular therapeutic as a transformative treatment for type 1 diabetes. The company's adoptive immunoregulatory cell therapy is currently undergoing preclinical testing across a range of autoimmune and inflammatory diseases. The research program will be led by Paolo Fiorina, M.D., Ph.D., Assistant Professor of Pediatrics at Boston Children's Hospital and Harvard Medical School. Under the agreement, Dr. Fiorina will investigate the potential of Fate's PD-L1 programmed CD34+ cellular therapeutic to abrogate autoimmune activity responsible for the destruction of pancreatic beta cells and the development of type 1 diabetes. Preclinical data from the Fiorina laboratory shows that genetically engineered PD-L1+ hematopoietic cells adoptively transferred into hyperglycemic mice traffic to the pancreas, reduce aberrant T cell activity and revert hyperglycemia in a well-established murine model of type 1 diabetes.

Juno Therapeutics, Inc. Announces Research Collaboration and License Agreement with Fate Therapeutics, Inc

Juno Therapeutics, Inc. and Fate Therapeutics, Inc. announced a strategic research collaboration and license agreement to identify and utilize small molecules to enhance therapeutic potential of Juno's genetically-engineered T cell product candidates for cancer patients. The collaboration brings together Juno's expertise in the development of chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular immunotherapies and Fate's innovative platform for programming the biological properties and in vivo therapeutic potential of hematopoietic cells. Through the four-year R&D collaboration, Fate will be responsible for screening and identifying small molecules that modulate the biological properties of engineered T cells. Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating Fate's small molecule modulators. Juno has the option to extend the exclusive research term for two years through an additional payment and continued funding of collaboration activities. Financial terms of the agreement include an upfront payment to Fate of $5 million and the purchase by Juno of one million shares of Fate common stock at $8.00 per share. Juno will fund all mutual collaboration activities for an exclusive four-year research term. For each product developed by Juno that incorporates modulators identified through the collaboration, Fate is eligible to receive approximately $50 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales. Fate retains exclusive rights to its intellectual property for all purposes outside of programmed CAR and TCR immunotherapies.

Fate Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Fate Therapeutics, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $7,324,000 against $6,937,000 a year ago. Net loss and comprehensive loss was $7,881,000 against $6,980,000 a year ago. Net loss per common share, basic and diluted was $0.38 against $0.34 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FATE:US $6.69 USD +0.22

FATE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FATE.
View Industry Companies

Industry Analysis


Industry Average

Valuation FATE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FATE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at